| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ofatumumab |
| Brand | Arzerra® |
| Indication | In combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy. |
| Assessment Process | |
| Rapid review commissioned | 13/10/2014 |
| Rapid review completed | 18/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended at the submitted price. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.